

Company Name	Company Description in 2-3 sentences	Total Team	Investment Highlights	Healthcare Sector	traction to date	Sales	fund raising	pre-money valuation?	Regulation	
Alpha Tau Medical Ltd.	Alpha Tau Medical focuses on research, development and commercialization of Alpha DART (Distant Alpha-Derived Anticancer Therapy) for a highly precise and customized treatment for solid tumors. DART utilizes Alpha-Derived Anticancer Therapy for the tumor high energy radiation. The technology was published in 12 articles in peer-reviewed scientific journals and has shown to be safe and effective both in preclinical and clinical trials.	10-50	The company has achieved highly promising preliminary results in SCC Head & Neck and Skin clinical trials. The Alpha DART system was shown to be safe and effective, and not require any special shielding or special equipment and only needed for a duration of about 10 minutes. The results of the study proved the ability of the Alpha DART to effectively destroy solid tumors with no systemic adverse events. Based on years of preclinical studies that showed efficacy and safety for all solid tumors tested, the company is now expanding its clinical research to further indications such as prostate cancer, breast cancer, gastrointestinal cancer, colorectal cancer and pancreatic cancer. The Alpha Tau Medical management team has past gained experience in achieving CE and FDA approvals, global product launch and fundraising, including IPO.	Medical device	Valuing the Alpha DART as a highly potent and confirmed treatment for solid tumors, leading clinicians and cancer researchers are now looking for ways to further clinical trials on various indications. The company received IRB approvals to first-in-human clinical trials and established productive relationships with major cancer hospitals, such as Memorial Sloan-Kettering Cancer Center (MSK), Gustave Roussy (France), European Institute of Oncology (EIO) and IGC (Ireland) through its investment in research.	No	The company has recently secured funds for its next milestones.	\$20-30M USD	CE, FDA	Already did first in man
Brainway	Brainway's innovation is in developing and commercializing breakthrough technology in neurobiology that treats psychiatric neurological conditions, such as severe depression, anxiety and smoking cessation, epilepsy, stroke rehabilitation and more.	70	Already selling devices, poised for rapid growth, unique clinical pipelines, strong patents, huge market	Medical device	~10m USD annual sales	Yes	Yes	\$100M	FDA, CE	
EchoCore Technologies	EchoCore develops a non-invasive, elderly-care, home monitoring system that automatically detects and alerts on emergency or abnormal situations at home. The EchoCore device is a connected smart home device that detects various falls, which are the biggest problem of elderly and other abnormal situations, such as respiratory distress (unconsciousness or sleep apnea) and changes from normal (e.g. daily living, eating, sleeping). It is based on a unique active IR sensor that doesn't compromise the senior's privacy, health, comfort, and causes a minimal ambient lighting through the wall with a single sensor.	5	There are various solutions in market. Most of the solutions are wearable devices. Others are either camera based solution or distributed sensors. However, when it comes to the private homes (e.g. the senior apartment), none of them are acceptable. The sensors are not comfortable to wear a device for 24/7. They don't like to have a camera, require cables and do not allow to have a lot of wires in their home. EchoCore proposes a disruptive solution (non-wearable, and non-intrusive) that can cover the complete apartment with a single device (can "walk" through the walls). The company has several successful patents and has a strategic collaboration with key companies.	Healthcare IT	EchoCore works with key elderly care companies such as senior living facilities, senior home care operators. We started pilots with several companies in the US and got a very positive feedback.	No	Yes, Round A	\$5M	CE	
Gordan Surgical	Medtronic Surgical Navigation ("MedNav") is an integrated patient system (often surgically implanted) that provides a simple, secure and safe solution to open and sustain close the abdominal wall during laparoscopic bariatric revisional procedures. They may be used - require minimum training. Device capabilities and CE/DE - up to 10 minutes per part. A combination of sophisticated tools that are not currently available to technical community for revisional safely, specifically compared to other closure device.	and additional 1.5	The company has received CE mark and FDA approval. We have shown more than 100 successful surgeries in pre-clinical surgeries by our	Medical device	Innovative alternative product, ready for commercialization	No	Yes, 100k USD	\$20-30M USD	FDA, CE, already did first in man, during international, CE, Distribution agreements	
Phar Health	Phar develops the first respiratory digital therapy to monitor and prevent pulmonary exacerbation, stress and anxiety. Phar's solution optimizes the way patients breathe with their pills, regulate stress and anxiety. The solution combines the science of heart rate variability (HRV) (biometric) sensing, IT, cognitive science, and a patient pricing algorithm to predict and prevent exacerbations.	9	The Phar solution is designed to help 50 million Asthma patients which are currently looking for alternative therapy for Asthma where Phar offers a clinically proven digital therapy to monitor, predict and prevent Asthma attacks. -What unique quantitative digital therapy in Asthma area has already demonstrated efficacy - our preliminary clinical trial results showing improvement in Asthma control of 32% and reduction of rescue medication intake of 25%, leading to major savings for the patient or payor/home which save an additional USD 1000-1500 every when Asthma is uncontrolled. -Globalized solution which is already used to pharmacies and biotech/biotech professionals in the USA, India and Israel. -Regulatory uses as current sensors are already FDA/CE/CFDA approved and are manufactured in China. -Phar's app ranked among top 10 medical apps for 2015 by Medical, the largest medical technology conference in the world, Düsseldorf, Germany 2015. -What solution was chosen by Novartis as a promising solution for Asthma, Vha Technologies, the largest digital conference in the world, Paris, France 2016. -What was awarded by the German Topical Health Minister as the most revolutionary health care startup for 2016 during World Health Summit (WHS), Berlin, Germany, 2016. WHS is the most prestigious health care summit which bring together world health leaders to set the global health agenda and priorities. -What opened the Indian market last year collaborating with Apollo Hospitals Group (the largest private health care provider in India with 480 patients) to conduct clinical trial and promote the product together. -Phar has a leading talent team with business, marketing, IT specialists and a renowned respiratory MD and biotech/biotech psychologist. Phar already impacts to team in UK and China. -What technologies have the potential to make further major impacts on additional markets: Stress management, COPD, Blood pressure, Heart rhythm.	Medical device	sales of more than 1000 units for pharmacy and psychologists. Phar's Asthma clinical trial preliminary results with Apollo Hospital Group show: 1) Improvement of 32% in Asthma control; 2) Reduction of 25% in rescue medication intake; 3) Improvement in the quality of patients life.	Yes	Yes	USD 10M	FDA, CE, CFDA	
Kadmonim Ltd	Kadmonim (NYSE: KOST) develops human pluripotent stem cell based cell therapies for A	33 Employees	Kadmonim is about to start clinical trials in the end of 2017 for treatment of ALS in Israel and in the US with the FDA. Kadmonim	Therapeutics	Kadmonim is backed by the Tel-Aviv SE (NYSE: KOST). The company has raised about	Product	Yes	\$17M	After National Commission approval. About to commence phase 1/1a clinical trials in Israel	
LIApp	LIApp developed a patented smart technology that can overcome the biggest barrier and c	8 people	LIApp technology presents a critical need in the poultry industry which is to know what happens in real time in the aggro-business during	Agribusiness	LIApp team is composed of engineers, algorithm developers and experienced business	No	Yes	20M USD	We completed several pilots and feedback and get a product fit.	
Miglitest	Miglitest has been a well-known technology firm internationally - accelerating how growth	7	We had a unique technology, patented product and have no competitors. The device requires minimum 5 minutes of use. Our production cost is very low. We have started developing applications to the Chinese market (submitted as IASG).	Medical device	We have made 10 marketing efforts and sold more than 1000 units to individual users.	Yes	Yes, we are looking to	20M	CE, already did first in man	
Mediab Ltd	The company has a unique technology for pain relief, handheld programmable device bring	10 employees	The technology was approved by hospitals and formal institutions (FDA and CE) and is being in the market since 2015. We believe the market here is huge Chinese partner in order to expand in China.	Medical device	Not clear enough.	Yes, Medib	Yes	10M USD	FDA, CE, already did first in man. We have a business developer who speaks Chinese at	
NewPhase	NewPhase have developed a disruptive SYSTEMIC cancer treatment which will transform t	12	Cancer is #2 cause of death. Our treatment is 100% effective and we transform all cancer to a chronic ailment. Huge market. We are treating diseases in chronic ailment, enabling people to live 10 and productive lives.	Medical device	Seeking US FDA human trials	No	Yes	10	OK from FDA for first in man	

<p><b>Nucleix</b></p> <p>Nucleix is a highly innovative company for cancer detection in body fluids. We use unique diagnostics and bio-chemical tests that provide an early diagnosis performance.</p>	<p>22</p> <p>Innovation - We make superior tests for cancer detection, we developed a lung cancer screening test in blood samples with the best-in-class performance. Lung cancer is a huge problem in China, and provides a multi-billion dollar opportunity in China alone. Our technology is very unique.</p> <p>Market - We validated our tests in several clinical studies, we have the best-in-class results for both lung cancer and bladder cancer.</p> <p>Leadership - We are led by highly experienced, bright and successful entrepreneurs. We are also working with the leading physicians in our fields in CE and Europe.</p> <p>Financial support - we are backed by leading investors such as Otsuka, Aurum Ventures, Zuber Zingel and others.</p>	<p>Diagnosis</p>	<p>Developed the technology platform that allows us to build a test for any cancer. We developed tests with best-in-class results for lung cancer and bladder cancer. We finished several clinical studies in leading centers in Europe, and we have several ongoing studies in leading centers in CE and Europe. We recently received the CE mark. We are very competitive given from the European Union (Horizon 2020 program).</p>	<p>No</p>	<p>Yes</p>	<p>Not be disclosed separately.</p>	<p>CE</p>
<p><b>CEL Innovations</b></p> <p>CEL Innovations is specialized in optics development. Now days, we are developing over 10</p>	<p>3</p> <p>Stomach cancer is the most common cancer in the western world. The recommendation is to perform mostly self-screening to identify skin</p>	<p>Medical device</p>	<p>We have pending patent on our technology and first prototype.</p>	<p>No</p>	<p>Yes</p>	<p>\$5,000,000</p>	<p>Already did first in man</p>
<p><b>OrthoCyber Medical Ltd</b></p> <p>OrthoCyber Medical Ltd is a leading medical device company that has perfected the art of medical-device development by combining years of design experience, medical background and boutique, research and development capabilities, with our proven IP portfolio and processes we provide superior clinical solutions.</p> <p>OrthoCyber Medical Ltd Controls 80% of the most sophisticated Orthopaedic (MO), using R&amp;D group and highly skilled experienced management team.</p>	<p>4</p> <p>The OrthoCyber SDCR Product is a new surgical system offering enhanced outcomes for orthopaedic surgeons and their patients. The new technology design provides surgeons with superior control, accuracy and performance. This results in reduced surgical time, damage and trauma to tissues and leads to faster operations. Proximal results and an overall improvement in post-surgery healing. Unique patented algorithm manages and controls the OrthoCyber SDCR system. Implementation on real time basis all emergency settings. Thus, Misalignment is stable after distal planning. In all surgical, we will do correct instrumenting and closed loop control. For example, the motion of the drill bit may be stopped if a certain pre-determined penetration depth has been achieved (automated stop), or stopping the drill bit penetration and rotation if the removal of bone cannot be detected.</p> <p>Valid established database (consists of huge variety of orthopaedic statistics) enables patient operation customization providing the algorithm the necessary comprehensive information.</p>	<p>Medical device</p>	<p>Proof of concept: Working Group: Bone Flow, Algorithm: IP + FCT + US (FC) applications, Registered: Post-Regulatory Plan completed: CE - Class II - CE - Class III, CE-Sub: within 1-2 months. Strong Team: Founders: Engineers and Experts</p>	<p>No</p>	<p>Yes</p>	<p>\$3,000,000 USD</p>	<p>During Annual visit</p>
<p><b>OrthoKhemica</b></p> <p>We develop spinal implants, their product is artificial cervical disc.</p>	<p>5</p> <p>we believe you will have a chance to multiple your product in 10-30 times</p>	<p>Medical device</p>	<p>we have CE Mark and patients implanted with our disc in Germany</p>	<p>yes</p>	<p>yes</p>	<p>\$7.5M</p>	<p>CE</p>
<p><b>Polypil Ltd</b></p> <p>Polypil is an emerging specialty pharmaceutical company engaged in PLEX™ technology</p>	<p>50</p> <p>Continuity enables local industry platform for radiolabelled drug high and potentially low, initial launch, followed by low short effective launch. This solution is also non-toxic and with broad control.</p> <p>PLEX technology allow for pre-determined, controlled release rate of broad spectrum drug cycle with high and effective local drug concentration over a significant period of time (weeks to months). Our main objective: treatment against all drug-resistant infections (DRIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). DRIs have substantial negative impact on patients, clinical outcomes and also pose a significant healthcare system burden. PLEX™ has high potential to make this problem.</p>	<p>Therapeutics</p>	<p>The safety and efficacy of PLEX™ based therapy 1500 was demonstrated in a pilot study</p>	<p>No</p>	<p>Yes</p>	<p>\$30M pre-rev</p>	<p>Already did first in man. During 3 clinical studies, one passed for CE approval</p>
<p><b>Sensolve Ltd.</b></p> <p>Sensolve Ltd. is a medical device start-up company developing a Minimally Invasive Micro</p>	<p>9-10</p> <p>The company plans to offer the new gold standard in Glioma treatment and combined Glioma/Cancer treatment</p>	<p>Medical device</p>	<p>Managed to achieve all technical goals in time. Raised \$2M to date from various angels</p>	<p>No</p>	<p>Yes</p>	<p>\$2M</p>	<p>CE, Already did first in man</p>
<p><b>Isis Medical Tech</b></p> <p>With a goal of saving millions of lives by enabling optimal treatment of heart failure patients.</p>	<p>13</p> <p>We provide a solution for one of the greatest challenges of modern-day healthcare using a novel technology with a remarkable barrier to entry.</p> <p>A big market, disruptive solution by a talented and highly motivated team.</p>	<p>Medical device</p>	<p>We have developed a system, proved it in pig animals and we are entering human phase</p>	<p>No</p>	<p>Yes</p>	<p>\$10 million</p>	<p>During Annual visit</p>
<p><b>Apfita LTD.</b></p> <p>Apfita has developed a breakthrough minimally invasive delivery non-toxic system for minimally invasive neuro-recovery following stroke and other cerebral vascular system. Apfita uses only the most advanced patient-proven and proven and is inserted through a small incision in the patient's back, resulting in minimal surgery time and significant reduction in risk, risk, and recuperation period.</p> <p>With over 100 surgeons done, clinical results are excellent while patient and surgeon satisfaction is very high. The company has CE and selling its products and has submitted to FDA for approval.</p>	<p>5 people + fundraising</p> <p>Apfita is a game changing company in huge spine market. Its proven technology presents a unique opportunity for patients, surgeons and medical able to make the life of countless patients better. The company is already in commercial phase and is looking to expand to more recent including CE and Europe.</p>	<p>Medical device</p>	<p> traction is astounding. The company raises over \$7M from investors. The products are sold in many countries in Europe and is about to make it in Canada and Singapore. Significant number of spine surgeons use the device and are enthusiastic to start using it.</p>	<p>Yes</p>	<p>Yes</p>	<p>\$4M</p>	<p>CE</p>
<p><b>BrainC Technologies</b></p> <p>BrainC Technologies is a disruptive, data driven, clinical stage medical company that aims to significantly improve neuro-recovery following stroke and other cerebral vascular system. BrainC uses only the most advanced patient-proven and proven and is inserted through a small incision in the patient's back, resulting in minimal surgery time and significant reduction in risk, risk, and recuperation period.</p> <p>With over 100 surgeons done, clinical results are excellent while patient and surgeon satisfaction is very high. The company has CE and selling its products and has submitted to FDA for approval.</p>	<p>7</p> <p>We're addressing one of World's &amp; China's in particular huge unmet market - recovering paralyzed people after stroke, using innovative, Cloud Connected medical device and advanced Machine Learning algorithms.</p>	<p>Medical device</p>	<p>The clinical trials have demonstrated 100% effect, clinical trials have already shown real signs of life. We have been selected by the 100 Top 200 Startups 17 of 10 companies in Israel, and by Google Launchpad Machine Learning launch camp 11 of 10 companies in Israel. Company has raised to date a \$2M from leading investors and angels. BrainC's team and advisory board boasts a unique, multidisciplinary group of leaders in specific fields including technology, neural sciences research, US FDA and machine learning, analytics in medicine with international medical device business and regulatory. Our team's composition of leading experts in it has some of the world leading names in the field of neuro-recovery in robotics based. One example, is Prof. Avner Barak, VP World Stroke Organization.</p>	<p>No</p>	<p>Within a year from now</p>	<p>\$10-20M</p>	<p>Already did first in man</p>
<p><b>PRC Cardio-Care Ltd.</b></p> <p>The company develops innovative devices to open and clear Coronary Total Occlusion and other occluded arteries. The main patent based design allowed the design for safety to proceed but we have strong team to integrate other technologies to this device. The market is US\$ multi Billion in size.</p>	<p>About 7-8 top Advisory Board</p> <p>We bring to the market solution that not available as commercial offer. There is tremendous need we see strong team.</p>	<p>Medical device</p>	<p>proven technology and strong experienced team</p>	<p>No</p>	<p>Yes</p>	<p>US\$ 4,000,000</p>	<p>some initial tests in pigs</p>